Myasthenia Gravis Research Highlights: AAN 2024
| Overview / Abstract: |
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction. Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as well as real world data, were presented at the American Academy of Neurology Annual Meeting (AAN 2024) held in Denver, CO. This CME activity, hosted by Nicholas Silvestri, MD, of the University of Buffalo, provides an overview of the latest clinical research presented at AAN 2024 focused on myasthenia gravis. |
|
Expiration |
Jun 30, 2025 |
|
Discipline(s) |
Physician CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
0.5 hours |
|
Accreditation |
American Academy of CME |
|
Presenters / Authors / Faculty |
Nicholas Silvestri, MD |
|
Sponsors / Supporters / Grant Providers |
argenx US, Inc. and UCB Inc. |
|
Keywords / Search Terms |
CheckRare rare disease, myasthenia graves, rare neurology disorder, CME, AAN, Treatment of myasthenia gravis, individualized medicine, comorbidities, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, zilucoplan, Clinical trial data, real world data, Free CE CME |
|